These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 25754323)

  • 1. The Baroreflex in Hypertension.
    Fernandez G; Lee JA; Liu LC; Gassler JP
    Curr Hypertens Rep; 2015 Mar; 17(3):19. PubMed ID: 25754323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system. Activation of the sympathetic nervous system is the dominant contributor to systemic hypertension.
    Negrao CE; Negrao MV
    J Appl Physiol (1985); 2010 Dec; 109(6):2006. PubMed ID: 21188817
    [No Abstract]   [Full Text] [Related]  

  • 3. Sympathetic and baroreflex function in hypertension: implications for current and new drugs.
    Grassi G
    Curr Pharm Des; 2004; 10(29):3579-89. PubMed ID: 15579055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New approaches in the treatment of hypertension.
    Oparil S; Schmieder RE
    Circ Res; 2015 Mar; 116(6):1074-95. PubMed ID: 25767291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sympathetic nervous system: role in hypertension and in chronic kidney disease.
    Grassi G; Bertoli S; Seravalle G
    Curr Opin Nephrol Hypertens; 2012 Jan; 21(1):46-51. PubMed ID: 22080859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baroreflex failure.
    Heusser K; Tank J; Luft FC; Jordan J
    Hypertension; 2005 May; 45(5):834-9. PubMed ID: 15837841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistent sympathetic activation during chronic antihypertensive therapy: a potential mechanism for long term morbidity?
    Fu Q; Zhang R; Witkowski S; Arbab-Zadeh A; Prasad A; Okazaki K; Levine BD
    Hypertension; 2005 Apr; 45(4):513-21. PubMed ID: 15738344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electrical carotid sinus stimulation in treatment resistant arterial hypertension.
    Jordan J; Heusser K; Brinkmann J; Tank J
    Auton Neurosci; 2012 Dec; 172(1-2):31-6. PubMed ID: 23146623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antihypertensive drugs and the sympathetic nervous system.
    Del Colle S; Morello F; Rabbia F; Milan A; Naso D; Puglisi E; Mulatero P; Veglio F
    J Cardiovasc Pharmacol; 2007 Nov; 50(5):487-96. PubMed ID: 18030057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of antihypertensive therapies on the sympathetic nervous system.
    de Champlain J; Karas M; Toal C; Nadeau R; Larochelle P
    Can J Cardiol; 1999 Mar; 15 Suppl A():8A-14A. PubMed ID: 10205251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The interplay between sympathetic overactivity, hypertension and heart rate variability (review, invited).
    Drenjancevic I; Grizelj I; Harsanji-Drenjancevic I; Cavka A; Selthofer-Relatic K
    Acta Physiol Hung; 2014 Jun; 101(2):129-42. PubMed ID: 24901074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system. Systemic hypertension--involvement of the CNS to this complex puzzle.
    Moreira TS; Takakura AC; Antunes VR
    J Appl Physiol (1985); 2010 Dec; 109(6):2004. PubMed ID: 21188814
    [No Abstract]   [Full Text] [Related]  

  • 13. Antihypertensive treatment and sympathetic excitation.
    Malliani A; Montano N
    Hypertension; 2005 Sep; 46(3):e8; author reply e8. PubMed ID: 16123377
    [No Abstract]   [Full Text] [Related]  

  • 14. Baroreceptor Stimulation for Resistant Hypertension.
    Yoruk A; Bisognano JD; Gassler JP
    Am J Hypertens; 2016 Dec; 29(12):1319-1324. PubMed ID: 27444637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Refractory hypertension: diagnosis and treatment optimization].
    Fursov AN; Chernetsov VA; Chernov SA; Potekhin NP; Sokolianskiĭ NV; Zakharova EG; Liapkova NB
    Voen Med Zh; 2014 May; 335(5):22-5. PubMed ID: 25286559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Point: Chronic activation of the sympathetic nervous system is the dominant contributor to systemic hypertension.
    Esler M; Lambert E; Schlaich M
    J Appl Physiol (1985); 2010 Dec; 109(6):1996-8; discussion 2016. PubMed ID: 20185633
    [No Abstract]   [Full Text] [Related]  

  • 17. New therapies for arterial hypertension.
    Pagliaro B; Santolamazza C; Rubattu S; Volpe M
    Panminerva Med; 2016 Mar; 58(1):34-47. PubMed ID: 26730462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baroreflex gain and vasomotor sympathetic modulation in resistant hypertension.
    Freitas IMG; de Almeida LB; Pereira NP; Mira PAC; de Paula RB; Martinez DG; Toschi-Dias E; Laterza MC
    Clin Auton Res; 2017 Jun; 27(3):175-184. PubMed ID: 28386627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroadrenergic disarray in pseudo-resistant and resistant hypertension.
    Grassi G; Bombelli M; Buzzi S; Volpe M; Brambilla G
    Hypertens Res; 2014 Jun; 37(6):479-83. PubMed ID: 24572914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The sympathorenal axis in hypertension and heart failure.
    Goldsmith SR; Sobotka PA; Bart BA
    J Card Fail; 2010 May; 16(5):369-73. PubMed ID: 20447571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.